Recent Advances on Drug Treatments of Rheumatoid Arthritis

doi:10.21127/yaoyimr20210012

Abstract

Abstract: Rheumatoid arthritis is a chronic autoimmune disorder caused by persistent activation of immune system. Rheumatoid arthritis is the most prevalent form of inflammatory arthritis and always has critical consequences to the joints. Reducing pain, decreasing inflammation and blocking immune response are the main ideas for the treatment of rheumatoid arthritis. There are several therapeutic drugs are available for rheumatoid arthritis: nonsteroidal anti-inflammatory drugs, disease-modifying anti-rheumatic drugs, and biologic anti-rheumatic drugs. All these drugs are used alone or in combination with methotrexate, which have produced a remarkable impact on the occurrence and development of rheumatoid arthritis. Herein, we summarized the treatment options and some new drugs.

Key words: rheumatoid arthritis, nonsteroidal anti-inflammatory drugs, disease-modifying anti-rheumatic drugs, biologic anti-rheumatic drugs

Chunxia Gan, Mingzhen Yu, Ergu Chen, Xuanjun Wang, Huanhuan Xu. Recent Advances on Drug Treatments of Rheumatoid Arthritis[J]. Medicine Research, 2022, 6(1-2): 210012-210012.

References

[1] Smolen, J. S.; Aletaha, d.; McInnes, I. Rheumatoid arthritis. Lancet 2016, 388, 2023–2038.
[2] Young, A.; Koduri, G. Extra-articular manifestations and complications of rheumatoid arthritis. Best Pract. Res. Clin. Rheumatol. 2007, 21, 907–927.
[3] Grassi, W.; De Angelis, R.; Lamanna G.; Cervini, C. The clinical features of rheumatoid arthritis. Eur. J. Radiol. 1998, 27, 18–24.
[4] Aletaha, D.; Smolen, J. S. Diagnosis and management of rheumatoid arthritis: a review. Jama 2018, 320, 1360–1372.
[5] Cojocaru, M.; Cojocaru, I. M.; Silosi, I.; Vrabie, C. D.; Tanasescu, R. Extra-articular manifestations in rheumatoid arthritis. Maedica (Bucur) 2010, 5, 286–291.
[6] Mysler, E.; Caubet, M.; Lizarraga, A. Current and Emerging DMARDs for the Treatment of Rheumatoid Arthritis. Open Access Rheumatol.: Res. Rev. 2021, 13, 139–152.
[7] Gaffo, A.; Saag, K. G.; Curtis, J. R. Treatment of rheumatoid arthritis. Am. J. Health-Syst. Pharm. 2006, 63, 2451–2465.
[8] Abbasi, M.; Mousavi, M. J.; Jamalzehi, S.; Alimohammadi, R.; Bezvan, M. H.; Mohammadi, H.; Aslani, S. Strategies toward rheumatoid arthritis therapy; the old and the new. J. Cell. Physiol. 2019, 234, 10018–10031.
[9] Drosos, A. A.; Pelechas, E.; Voulgari, P. V. Treatment strategies are more important than drugs in the management of rheumatoid arthritis. Clin. Rheumatol. 2020, 39, 1363–1368.
[10] Fidahic, M.; Kadic, A. J.; Radic, M.; Puljak, L. Celecoxib for rheumatoid arthritis. Cochrane. Database. Syst. Rev. 2017, 6, 1–109.
[11] Singh, D. P.; Borse, S. P.; Nivsarkar, M. Clinical importance of nonsteroidal anti-inflammatory drug enteropathy: the relevance of tumor necrosis factor as a promising target. Trans. Res. 2016, 175, 76–91.
[12] Sizova, L. Approaches to the treatment of early rheumatoid arthritis with disease-modifying antirheumatic drugs. Br. J. Clin. Pharmacol. 2008, 66, 173–178.
[13] Donahue, K. E.; Schulman, E. R.; Gartlehner, G.; Jonas, B. L.; Viswanathan, M. Comparative Effectiveness of Combining MTX with Biologic Drug Therapy Versus Either MTX or Biologics Alone for Early Rheumatoid Arthritis in Adults: a Systematic Review and Network Meta-analysis. J. Gen. Intern. Med. 2019, 34, 2232–2245.
[14] Katturajan, R.; Mahaboobkhan, R.; Vijayalakshmi, S.; Prince, S. E. Molecular toxicity of methotrexate in rheumatoid arthritis treatment: A novel perspective and therapeutic implications. Toxicology 2021, 461, 1–8.
[15] Upchurch, K. S.; Kay, J. Evolution of treatment for rheumatoid arthritis. Rheumatology (Oxford) 2012, 51, 28–36.
[16] Weaver, A. L. The impact of new biologicals in the treatment of rheumatoid arthritis. Rheumatology (Oxford) 2004, 43, 17–23.
[17] Maini, R.; St Clair, E. W.; Breedveld, F.; Furst, D.; Kalden, J.; Weisman, M.; Smolen, J.; Emery, P.; Harriman, G.; Feldmann, M. Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet 1999, 354, 1932–1939.
[18] St Clair, E. W.; Van Der Heijde, D. M. F. M.; Smolen, J. S.; Maini, R. N.; Bathon, J. M.; Emery, P.; Keystone, E.; Schiff, M.; Kalden, J. R.; Wang, B. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheu. 2004, 50, 3432–3443.
[19] Moreland, L. W.; Weinblatt, M. E.; Keystone, E. C.; Kremer, J. M.; Martin, R. W.; Schiff, M. H.; Whitmore, J. B.; White, B. W. Etanercept treatment in adults with established rheumatoid arthritis: 7 years of clinical experience. J. Rheumatol. 2006, 33, 854–861.
[20] Kremer, J. M.; Weinblatt, M. E.; Bankhurst, A. D.; Bulpitt, K. J.; Fleischmann, R. M.; Jackson, C. G.; Atkins, K. M.; Feng, A.; Burge, D. J. Etanercept added to background methotrexate therapy in patients with rheumatoid arthritis: continued observations. Arthritis Rheum. 2003, 48, 1493–1499.
[21] Lu, X.; Hu, R.; Peng, L.; Liu, M.; Sun, Z. Efficacy and Safety of Adalimumab Biosimilars: Current Critical Clinical Data in Rheumatoid Arthritis. Front. Immunol. 2021, 12, 1–9.
[22] Lee, Y. H.; Song, G. G. Comparative efficacy and safety of adalimumab biosimilars and adalimumab in patients with rheumatoid arthritis presenting an insufficient response to methotrexate: a network meta-analysis. Z. Rheumatol. 2021, 1–7.
[23] Clowse, M. E.; Scheuerle, A. E.; Chambers, C.; Afzali, A.; Kimball, A. B.; Cush, J. J.; Cooney, M.; Shaughnessy, L.; Vanderkelen, M.; Förger, F. Pregnancy outcomes after exposure to certolizumab pegol: updated results from a pharmacovigilance safety database. Arthritis Rheumatol. 2018, 70, 1399–1407.
[24] Pelechas, E.; Voulgari, P.; Drosos, A. Golimumab for Rheumatoid Arthritis. J. Clin. Med. 2019, 8, 387.
[25] Keystone, E. C.; Genovese, M. C.; Klareskog, L.; Hsia, E. C.; Hall, S. T.; Miranda, P. C.; Pazdur, J.; Bae, S. C.; Palmer, W.; Zrubek, J. Golimumab, a human antibody to tumour necrosis factor α given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study. Ann. Rheum. Dis. 2009, 68, 789–796.
[26] Pazmino, S.; Boonen, A.; De, Cock. D.; Stouten, V.; Joly, J.; Bertrand, D.; Westhovens, R.; Verschueren, P. Short-term glucocorticoids reduce risk of chronic NSAID and analgesic use in early methotrexate-treated rheumatoid arthritis patients with favourable prognosis: subanalysis of the CareRA randomised controlled trial. RMD Open 2021, 7, 1–6.
[27] Verschueren, P.; De, Cock. D.; Corluy, L.; Joos, R.; Langenaken, C.; Taelman, V.; Raeman, F.; Ravelingien, I.; Vandevyvere, K.; Lenaerts, J. Effectiveness of methotrexate with step-down glucocorticoid remission induction (COBRA Slim) versus other intensive treatment strategies for early rheumatoid arthritis in a treat-to-target approach: 1-year results of CareRA, a randomised pragmatic open-label superiority trial. Ann. Rheum. Dis. 2017, 76, 511–520.
[28] Bergantini, L.; d’Alessandro, M.; Cameli, P.; Vietri, L.; Vagaggini, C.; Perrone, A.; Sestini, P.; Frediani, B; Bargagli, E. Effects of rituximab therapy on B cell differentiation and depletion. Clin. Rheumatol. 2020, 39, 1415–1421.
[29] Chatzidionysiou, K.; Lie, E.; Nasonov, E.; Lukina, G.; Hetland, M. L.; Tarp, U.; Gabay, C.; van Riel, P. L. C. M.; Nordström, D. C.; Gomez-Reino, J. Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries. Ann. Rheum. Dis. 2011, 70, 1575–1580.
[30] Liu, M.; Yu, Y.; Hu, S. A review on applications of abatacept in systemic rheumatic diseases. Int. Immunopharmacol. 2021, 96, 1–10.
[31] Genovese, M. C.; McKay, J. D.; Nasonov, E. L.; Mysler, E. F.; da Silva, N. A.; Alecock, E.; Woodworth, T.; Gomez-Reino, J. J. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum. 2008, 58, 2968–2980.
[32] Burmester, G. R.; Lin, Y.; Patel, R.; Van Adelsberg, J.; Mangan, E. K.; Graham, N. M.; Van, Hoogstraten, H.; Bauer, D.; Vargas, J. I.; Lee, E. B. Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial. Ann. Rheum. Dis. 2017, 76, 840–847.
[33] Fischer, R.; Kontermann, R. E.; Pfizenmaier, K. Selective targeting of TNF receptors as a novel therapeutic approach. Front. Cell Dev. Biol. 2020, 8, 1–21.
[34] Richter, F.; Williams, S. K.; John, K.; Huber, C.; Fischer, R. The TNFR1 Antagonist Atrosimab Is Therapeutic in Mouse Models of Acute and Chronic Inflammation. Front. Immunol. 2021, 12, 1–14.
[35] Wang, Y.; Chen, S.; Du, K.; Liang, C.; Wang, S.; Evans, O. B.; Li, J.; Pang, X.; He, J.; Chang, Y. Traditional herbal medicine: Therapeutic potential in rheumatoid arthritis. J. Ethnopharmacol. 2021, 279, 1–21.